Compare AKA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKA | LUNG |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.4M | 57.9M |
| IPO Year | 2021 | 2020 |
| Metric | AKA | LUNG |
|---|---|---|
| Price | $9.27 | $1.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $24.33 | $5.38 |
| AVG Volume (30 Days) | 4.1K | ★ 501.7K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $90,497,000.00 |
| Revenue This Year | $6.14 | $2.48 |
| Revenue Next Year | $4.89 | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 4.44 | ★ 8.01 |
| 52 Week Low | $8.60 | $1.13 |
| 52 Week High | $16.38 | $3.88 |
| Indicator | AKA | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 68.55 |
| Support Level | $8.94 | $1.51 |
| Resistance Level | $11.57 | $1.93 |
| Average True Range (ATR) | 0.52 | 0.10 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 6.35 | 89.90 |
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.